SG11202003452XA - Dantrolene prodrugs and methods of their use - Google Patents
Dantrolene prodrugs and methods of their useInfo
- Publication number
- SG11202003452XA SG11202003452XA SG11202003452XA SG11202003452XA SG11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- dantrolene
- prodrugs
- dantrolene prodrugs
- Prior art date
Links
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 title 1
- 229960001987 dantrolene Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575124P | 2017-10-20 | 2017-10-20 | |
| US201862674422P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/056713 WO2019079721A1 (en) | 2017-10-20 | 2018-10-19 | Dantrolene prodrugs and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003452XA true SG11202003452XA (en) | 2020-05-28 |
Family
ID=64277793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003452XA SG11202003452XA (en) | 2017-10-20 | 2018-10-19 | Dantrolene prodrugs and methods of their use |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11352347B2 (en) |
| EP (1) | EP3697779A1 (en) |
| JP (2) | JP7252963B2 (en) |
| KR (1) | KR102652642B1 (en) |
| CN (1) | CN111344286A (en) |
| AU (2) | AU2018351494B2 (en) |
| BR (1) | BR112020007858A2 (en) |
| CA (1) | CA3079558A1 (en) |
| CO (1) | CO2020006193A2 (en) |
| IL (1) | IL274045B2 (en) |
| MA (1) | MA50403A (en) |
| MX (2) | MX2020003400A (en) |
| SG (1) | SG11202003452XA (en) |
| UA (1) | UA127738C2 (en) |
| WO (1) | WO2019079721A1 (en) |
| ZA (1) | ZA202002779B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018351494B2 (en) * | 2017-10-20 | 2023-09-14 | Eagle Research Labs Limited | Dantrolene prodrugs and methods of their use |
| US20220023319A1 (en) * | 2018-11-27 | 2022-01-27 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| WO2021207445A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating coronavirus infections |
| JP2023521163A (en) | 2020-04-10 | 2023-05-23 | イーグル ファーマスーティカルズ、インク． | Methods of treating SARS-COV-2 infection |
| EP4132517A1 (en) | 2020-04-10 | 2023-02-15 | Eagle Pharmaceuticals, Inc. | Methods of treating viral infections |
| IL296518A (en) | 2020-04-10 | 2022-11-01 | Eagle Pharmaceuticals Inc | Methods of treating severe acute respiratory syndrome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) * | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4137402A (en) | 1978-03-30 | 1979-01-30 | Morton-Norwich Products, Inc. | Quaternary ammonium salts of dantrolene and clodanolene |
| CA2702243C (en) | 2007-10-09 | 2016-06-21 | Us Worldmeds Llc | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| US8536213B2 (en) * | 2007-11-16 | 2013-09-17 | Nektar Therapeutics | Oligomer-dantrolene conjugates and related compounds |
| WO2009152205A1 (en) | 2008-06-10 | 2009-12-17 | Meta Cosmetics, Llc. | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| CA2906168C (en) | 2013-03-15 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| US9636327B2 (en) | 2013-05-06 | 2017-05-02 | University Health Network | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias |
| WO2014182944A1 (en) | 2013-05-08 | 2014-11-13 | Mangat Harpal S | Compositions and method for treatment of ischemic neuronal reperfusion injury |
| HUP1300720A2 (en) | 2013-12-12 | 2015-06-29 | Univ Szegedi | Pharmaceutical composition comprising dantrolene analogues for treating skin wounds |
| JPWO2015182625A1 (en) | 2014-05-26 | 2017-06-08 | 国立大学法人京都大学 | Ras activity inhibitor and use thereof |
| WO2016077706A1 (en) | 2014-11-13 | 2016-05-19 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| AU2018351494B2 (en) * | 2017-10-20 | 2023-09-14 | Eagle Research Labs Limited | Dantrolene prodrugs and methods of their use |
-
2018
- 2018-10-19 AU AU2018351494A patent/AU2018351494B2/en active Active
- 2018-10-19 UA UAA202002979A patent/UA127738C2/en unknown
- 2018-10-19 KR KR1020207013964A patent/KR102652642B1/en active IP Right Grant
- 2018-10-19 CN CN201880068207.9A patent/CN111344286A/en active Pending
- 2018-10-19 MX MX2020003400A patent/MX2020003400A/en unknown
- 2018-10-19 IL IL274045A patent/IL274045B2/en unknown
- 2018-10-19 CA CA3079558A patent/CA3079558A1/en active Pending
- 2018-10-19 SG SG11202003452XA patent/SG11202003452XA/en unknown
- 2018-10-19 WO PCT/US2018/056713 patent/WO2019079721A1/en unknown
- 2018-10-19 US US16/755,255 patent/US11352347B2/en active Active
- 2018-10-19 JP JP2020542711A patent/JP7252963B2/en active Active
- 2018-10-19 MA MA050403A patent/MA50403A/en unknown
- 2018-10-19 EP EP18801102.7A patent/EP3697779A1/en active Pending
- 2018-10-19 BR BR112020007858-1A patent/BR112020007858A2/en unknown
-
2020
- 2020-05-14 ZA ZA2020/02779A patent/ZA202002779B/en unknown
- 2020-05-20 CO CONC2020/0006193A patent/CO2020006193A2/en unknown
- 2020-07-13 MX MX2023010501A patent/MX2023010501A/en unknown
-
2022
- 2022-05-24 US US17/751,806 patent/US20220324850A1/en active Pending
-
2023
- 2023-01-23 JP JP2023007969A patent/JP2023061949A/en active Pending
- 2023-12-08 AU AU2023278113A patent/AU2023278113A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023278113A1 (en) | 2024-01-04 |
| KR20200072514A (en) | 2020-06-22 |
| IL274045B2 (en) | 2023-09-01 |
| MA50403A (en) | 2021-04-28 |
| RU2020116367A3 (en) | 2021-11-26 |
| US20200239455A1 (en) | 2020-07-30 |
| MX2023010501A (en) | 2023-09-20 |
| MX2020003400A (en) | 2020-09-18 |
| US20220324850A1 (en) | 2022-10-13 |
| JP2023061949A (en) | 2023-05-02 |
| ZA202002779B (en) | 2023-10-25 |
| UA127738C2 (en) | 2023-12-20 |
| EP3697779A1 (en) | 2020-08-26 |
| CO2020006193A2 (en) | 2020-08-21 |
| RU2020116367A (en) | 2021-11-22 |
| JP2021500405A (en) | 2021-01-07 |
| AU2018351494B2 (en) | 2023-09-14 |
| AU2018351494A1 (en) | 2020-04-30 |
| CA3079558A1 (en) | 2019-04-25 |
| IL274045B1 (en) | 2023-05-01 |
| WO2019079721A1 (en) | 2019-04-25 |
| US11352347B2 (en) | 2022-06-07 |
| IL274045A (en) | 2020-06-30 |
| CN111344286A (en) | 2020-06-26 |
| JP7252963B2 (en) | 2023-04-05 |
| BR112020007858A2 (en) | 2020-10-27 |
| KR102652642B1 (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | Novel micro-dystrophins and related methods of use | |
| GB2582482B (en) | CASZ compositions and methods of use | |
| IL278080B (en) | Riluzole prodrugs and their use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| IL274045B1 (en) | Dantrolene prodrugs and methods of their use | |
| HK1253049A1 (en) | Glycan-interacting compounds and methods of use | |
| IL282482A (en) | Protoxin-ii variants and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| IL282508A (en) | Protoxin-ii variants and methods of use | |
| IL265761A (en) | Terlipressin compositions and their methods of use | |
| PL3072560T3 (en) | Trampoline systems and methods of making and using the same | |
| GB201618414D0 (en) | Regulated cell lines and methods of use thereof | |
| IL283782A (en) | Anellosomes and methods of use | |
| IL260208A (en) | Cftr regulators and methods of use thereof | |
| SG11202011121UA (en) | Dantrolene formulations and methods of their use | |
| IL261794A (en) | Compositions and methods of their use | |
| GB201709186D0 (en) | Construction block and methods of use | |
| GB201720516D0 (en) | Flakes and methods of forming flakes |